Health And Pharma
WEBHealth & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
Lantidra: Revolutionary cell therapy for Type 1 diabetes earns FDA …
WEBJul 3, 2023 · Having conducted over 600 islet isolations and overseen successful Phase I, II, and III clinical trials for islet transplantation, CellTrans aspires to revolutionize treatment of diabetes and other endocrine disorders with cell-based therapies, including isolated islets, encapsulated islets, and human-derived stem cells.
AstraZeneca's Truqap Gets FDA Approval for Combined Breast …
WEBNov 18, 2023 · The Breakthrough of Truqap. The drug's effectiveness was underscored in the CAPItello-291 Phase III trial, where it demonstrated a 50% reduction in the risk of disease progression or death compared to Faslodex alone …
FDA Approves IMDELLTRA for Lung Cancer After a 40% Response …
WEBMay 17, 2024 · A New Era in SCLC Treatment. Small cell lung cancer, particularly the extensive-stage disease, has long been a formidable challenge in oncology, with fewer than 3% of patients surviving beyond five years post-diagnosis.IMDELLTRA's mechanism of action involves the activation of the patient's own T-cells to attack cancer cells expressing DLL3, offering a new hope for durable treatment responses.
Bayer's New Lung Cancer Drug Receives Critical FDA Breakthrough …
WEBMar 1, 2024 · Bayer's BAY 2927088, an investigational drug for non-small cell lung cancer with HER2 mutations, received the FDA's Breakthrough Therapy designation.
A New Era in Liver Disease: FDA Approves First Medication …
WEBMar 15, 2024 · “Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage. Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise” said Dr. Nikolay Nikolov, Director of Immunology and Inflammation in the FDA’s Center for Drug Evaluation ...
A New Era in Oncology: Programmable mRNA Therapies in the …
WEBApr 4, 2024 · The approach stands on the precipice of clinical application, with the initiation of Strand’s inaugural clinical trial in April. This trial aims to test a self-replicating mRNA molecule designed to provoke immune responses directly within tumors, such as melanoma and triple-negative breast cancer, marking a significant leap in …
Boehringer Ingelheim's P-II Trial Sparks Hope for Chronic Kidney ...
WEBNov 4, 2023 · A groundbreaking Phase II trial by Boehringer Ingelheim shows its novel aldosterone synthase inhibitor BI 690517, on top of empagliflozin, significantly reduces albuminuria in CKD patients by up to 39.5%.
Iptacopan, the First CI, Wins FDA Accelerated Approval for IgA …
WEBAug 8, 2024 · The FDA has granted accelerated approval to Fabhalta® (iptacopan) for reducing proteinuria in IgA nephropathy (IgAN) patients. Developed by Novartis, this first-in-class complement inhibitor demonstrated a 44% reduction in proteinuria in trials, marking a significant advancement in treatment options for this rare kidney disease.
Healthy Planet: How The Pharmaceutical Industry Can Reduce Its …
WEBAug 9, 2024 · A potential net increase of 529,000 adult deaths worldwide per year by 2050 due to climate change has been predicted, and even though the global pharmaceutical industry is in the business of keeping people healthy, it is also responsible for approximately 52 megatons of carbon dioxide equivalent emissions annually.. This equates to roughly 4.5 percent of total greenhouse gas emissions and ...